[Acute myeloid leukemia with t (8;21) translocation diagnosed at 21 weeks of gestation resulting in full-term delivery without chemotherapy].

Yuka Norihama, Moe Nomura, Yuki Oda, Yuki Kasuya, Tomomi Takei, Kota Sato, Mizuki Ogura, Taku Kikuchi, Yu Abe, Tadao Ishida, Yasuyo Kasai, Nobuhiro Tsukada
{"title":"[Acute myeloid leukemia with t (8;21) translocation diagnosed at 21 weeks of gestation resulting in full-term delivery without chemotherapy].","authors":"Yuka Norihama,&nbsp;Moe Nomura,&nbsp;Yuki Oda,&nbsp;Yuki Kasuya,&nbsp;Tomomi Takei,&nbsp;Kota Sato,&nbsp;Mizuki Ogura,&nbsp;Taku Kikuchi,&nbsp;Yu Abe,&nbsp;Tadao Ishida,&nbsp;Yasuyo Kasai,&nbsp;Nobuhiro Tsukada","doi":"10.11406/rinketsu.64.731","DOIUrl":null,"url":null,"abstract":"<p><p>A 28-year-old female was diagnosed with acute myeloid leukemia (AML) due to t (8;21) (q22;q22.1); RUNX1-RUNX1T1 at 21 weeks of gestation. Because no adverse prognostic genetic mutations were discovered, we decided to continue the pregnancy without chemotherapy for as long as possible. After careful monitoring with blood tests every two weeks, the disease did not progress until full-term, and a cesarean section was performed at 39 weeks of gestation. About two months after delivery, blasts in the peripheral blood increased to 46.5%, and myeloblasts in the bone marrow increased to 21.2%. The patient received idarubicin and cytarabine induction therapy, followed by three cycles of high-dose cytarabine consolidation therapy, and complete remission was maintained. Here we report a rare case who could avoid chemotherapy until full-term labor without progression of AML.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"[Rinsho ketsueki] The Japanese journal of clinical hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11406/rinketsu.64.731","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A 28-year-old female was diagnosed with acute myeloid leukemia (AML) due to t (8;21) (q22;q22.1); RUNX1-RUNX1T1 at 21 weeks of gestation. Because no adverse prognostic genetic mutations were discovered, we decided to continue the pregnancy without chemotherapy for as long as possible. After careful monitoring with blood tests every two weeks, the disease did not progress until full-term, and a cesarean section was performed at 39 weeks of gestation. About two months after delivery, blasts in the peripheral blood increased to 46.5%, and myeloblasts in the bone marrow increased to 21.2%. The patient received idarubicin and cytarabine induction therapy, followed by three cycles of high-dose cytarabine consolidation therapy, and complete remission was maintained. Here we report a rare case who could avoid chemotherapy until full-term labor without progression of AML.

[急性髓系白血病伴t(8;21)易位,妊娠21周诊断为足月分娩,无需化疗]。
1例28岁女性因t (8;21) (q22;q22.1)被诊断为急性髓性白血病(AML);妊娠21周时的RUNX1-RUNX1T1。由于没有发现不良预后的基因突变,我们决定在不化疗的情况下尽可能长时间地继续妊娠。在每两周进行一次血液检查的仔细监测后,疾病直到足月才进展,并在妊娠39周进行了剖宫产手术。分娩后约两个月,外周血中母细胞增加到46.5%,骨髓中成髓细胞增加到21.2%。患者接受依达柔比星和阿糖胞苷诱导治疗,随后进行3个周期的大剂量阿糖胞苷巩固治疗,维持完全缓解。在此,我们报告一个罕见的病例,可以避免化疗,直到足月分娩没有进展AML。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信